SciSparc opened at $0.40, in line with its previous close of $0.40. In the last trading session, the stock traded between $0.35 and $0.40. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in SciSparc is now worth
$ 0.00
Resulting in a loss of
$ 100.00 (100.00%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.05 (-11.60%)
Day High
$0.40
Day Low
$0.35
Day Open
$0.40
Prev Close
$0.40
Volume
77,214
1W Return
-30.84%
1M Return
-91.41%
3M Return
-94.76%
6M Return
-94.19%
1Y Return
-98.57%
Fundamentals
Market Cap ($ Mn)
1
PE Ratio
0.07
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-265.50%
EPS (TTM)
-
Investment Returns
1 Week
-30.84%
1 Month
-91.41%
3 Months
-94.76%
6 Months
-94.19%
9 Months
-93.62%
Financials
Quarterly
All values in $ Mn
0.0
Mar 18
0.0
Jun 18
0.0
Sep 18
0.0
Dec 18
0.0
Mar 19
0.0
Jun 19
Updates
27Oct
SciSparc cuts warrant exercise price to $1, expects $405k proceeds
SciSparc Ltd reduced warrant exercise price to $1 per share. Company expects aggregate gross proceeds of ~$405,728. Agreement is structured as a warrant inducement for existing holders.
17 days ago
22Oct
NeuroThera advances Tourette syndrome trial with QP batch release
NeuroThera Labs obtained European Qualified Person batch release for SCI-110. Clinical trial material shipments to three global sites expected in near term. Phase IIb trial for Tourette Syndrome advances toward patient enrollment. All participating sites completed initiation activities and await drug supply.
21 days ago
19Oct
SciSparc shifts strategic focus to agentic AI for cyber and finance
SciSparc pivots to agentic AI for cybersecurity and finance. Shares rose 18.18% to $4.290 on high volume. Market cap stands at $2.29 million amid micro-cap volatility. Existing pharma programs SCI-110 and SCI-210 remain active.
24 days ago
16Oct
SciSparc converts $2.02M note into shares at $1.50 each
SciSparc converts $2,023,039.21 in debt to equity. Conversion price set at $1.50 per ordinary share. No cash proceeds received by the company. Closing expected on October 16, 2026.
28 days ago
2Sep
SciSparc subsidiary NeuroThera pursues FDA orphan drug designation for SCI-110
SciSparc subsidiary NeuroThera Labs pursues FDA Orphan Drug Designation for SCI-110. Engagement with RK Strategies aims to strengthen U.S. market position and regulatory visibility. SCI-110 is a cannabinoid-based therapy for adult Tourette Syndrome currently in Phase IIb trials. Earlier Phase IIa studies showed an average tic reduction of 21%. NeuroThera also develops SCI-210 for autism spectrum disorder and status epilepticus.
2mo ago
1Sep
NeuroThera enrolls 26 children in SCI-210 autism trial targeting 60
SciSparc subsidiary NeuroThera Labs enrolls 26 children in SCI-210 ASD trial. Study targets 60 participants aged 5-18 at Soroka Medical Center in Israel. Trial evaluates dual-compound CBD and CannAmide vs CBD monotherapy. Primary endpoints include ABC-C questionnaire and CGI-I assessment.
